169 related articles for article (PubMed ID: 30926131)
1. Concurrent Use of Buprenorphine, Methadone, or Naltrexone Does Not Inhibit Ketamine's Antidepressant Activity.
Marton T; Barnes DE; Wallace A; Woolley JD
Biol Psychiatry; 2019 Jun; 85(12):e75-e76. PubMed ID: 30926131
[No Abstract] [Full Text] [Related]
2. Ketamine's rapid antisuicidal effects are not attenuated by Buprenorphine.
Hosanagar A; Schmale A; LeBlanc A
J Affect Disord; 2021 Mar; 282():252-254. PubMed ID: 33418374
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.
Williams NR; Heifets BD; Blasey C; Sudheimer K; Pannu J; Pankow H; Hawkins J; Birnbaum J; Lyons DM; Rodriguez CI; Schatzberg AF
Am J Psychiatry; 2018 Dec; 175(12):1205-1215. PubMed ID: 30153752
[TBL] [Abstract][Full Text] [Related]
4. Ketamine's potential as a rapid antidepressant was overplayed.
Zhang MW; Ho RC
BMJ; 2015 Aug; 351():h4467. PubMed ID: 26290499
[No Abstract] [Full Text] [Related]
5. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of opioid modulation in major depressive disorder.
Ehrich E; Turncliff R; Du Y; Leigh-Pemberton R; Fernandez E; Jones R; Fava M
Neuropsychopharmacology; 2015 May; 40(6):1448-55. PubMed ID: 25518754
[TBL] [Abstract][Full Text] [Related]
7. Methadone, Buprenorphine, and Naltrexone for the Treatment of Opioid Use Disorder in Pregnant Women.
Tran TH; Griffin BL; Stone RH; Vest KM; Todd TJ
Pharmacotherapy; 2017 Jul; 37(7):824-839. PubMed ID: 28543191
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine: prospective novel therapy for depression and PTSD.
Madison CA; Eitan S
Psychol Med; 2020 Apr; 50(6):881-893. PubMed ID: 32204739
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism.
Williams NR; Heifets BD; Bentzley BS; Blasey C; Sudheimer KD; Hawkins J; Lyons DM; Schatzberg AF
Mol Psychiatry; 2019 Dec; 24(12):1779-1786. PubMed ID: 31467392
[TBL] [Abstract][Full Text] [Related]
10. Overview of Drugs Used to Treat Opioid Use Disorder.
Aschenbrenner DS
Am J Nurs; 2018 Aug; 118(8):25. PubMed ID: 30048283
[No Abstract] [Full Text] [Related]
11. Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression.
Yang JJ; Wang N; Yang C; Shi JY; Yu HY; Hashimoto K
Biol Psychiatry; 2015 Feb; 77(3):e19-e20. PubMed ID: 25104172
[No Abstract] [Full Text] [Related]
12. Perioperative Considerations for the Patient with Opioid Use Disorder on Buprenorphine, Methadone, or Naltrexone Maintenance Therapy.
Harrison TK; Kornfeld H; Aggarwal AK; Lembke A
Anesthesiol Clin; 2018 Sep; 36(3):345-359. PubMed ID: 30092933
[TBL] [Abstract][Full Text] [Related]
13. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
[TBL] [Abstract][Full Text] [Related]
14. Use of Buprenorphine in treatment of refractory depression-A review of current literature.
Stanciu CN; Glass OM; Penders TM
Asian J Psychiatr; 2017 Apr; 26():94-98. PubMed ID: 28483102
[TBL] [Abstract][Full Text] [Related]
15. Help Is on the Way: Medicare Coverage of Opioid Treatment Programs.
Felix C; Sharfstein JM; Olsen Y
J Am Geriatr Soc; 2020 Mar; 68(3):637-640. PubMed ID: 31825528
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic and pharmacokinetic evaluation of buprenorphine + samidorphan for the treatment of major depressive disorder.
Ragguett RM; Rong C; Rosenblat JD; Ho RC; McIntyre RS
Expert Opin Drug Metab Toxicol; 2018 Apr; 14(4):475-482. PubMed ID: 29621905
[TBL] [Abstract][Full Text] [Related]
17. Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine's Rapid Antidepressant Properties.
Duncan WC; Slonena E; Hejazi NS; Brutsche N; Yu KC; Park L; Ballard ED; Zarate CA
Biol Psychiatry; 2017 Sep; 82(5):361-369. PubMed ID: 28457485
[TBL] [Abstract][Full Text] [Related]
18. Antipanic-like effect of esketamine and buprenorphine in rats exposed to acute hypoxia.
Maraschin JC; Frias AT; Hernandes PM; Batistela MF; Martinez LM; Joca SRL; Graeff FG; Audi EA; Spera de Andrade TGC; Zangrossi H
Behav Brain Res; 2022 Feb; 418():113651. PubMed ID: 34732354
[TBL] [Abstract][Full Text] [Related]
19. Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.
Nugent AC; Wills KE; Gilbert JR; Zarate CA
Psychiatry Res Neuroimaging; 2019 Jan; 283():64-66. PubMed ID: 30551012
[TBL] [Abstract][Full Text] [Related]
20. Ketamine as a novel antidepressant: from synapse to behavior.
Murrough JW
Clin Pharmacol Ther; 2012 Feb; 91(2):303-9. PubMed ID: 22205190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
